EUCTR2011-000155-16-IT进行中（未招募）不适用
Modulation of response to hormonal therapy with lapatinib and/or metformin in patients with HER2-negative, ER and/or PgR positive metastatic breast cancer with progressive disease after first-line hormonal therapy
FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI0 个研究点开始时间: 2012年3月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Female patients with a histologically or cytologically confirmed adenocarcinoma of the breast progressing from prior hormonal therapy 2. Receptor positive disease (ER+ and/or PgR+) 3. HER2 negative 4. Pre- and post-menopausal status 5. Documented disease progression after first-line hormone therapy 6. Age >= 18 years 7. Measurable or evaluable metastatic disease according to RECIST Criteria 1.1 8. Life expectancy > 3 months 9. ECOG Performance Status < 1 10. Adequate bone marrow, liver, and renal function as assessed by the following parameters: Hemoglobin > 9.0 g/dl Leucocytes count >= 3,000/mm3 Absolute neutrophil count (ANC)>= 1,500/mm3 Platelet count >= 100,000/mm3 Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <=2.5 x ULN <= 5 x ULN for patients with liver involvement) Albumine and total bilirubin <= 1.5 x ULN Prothrombin Time (PT) < 70 % Serum creatinine <= 1.4 mg/ml, creatinine clearance > 70 ml/min 11. Normal Respiratory Function and Saturation level > 90% 12. New York Hearth Association (NYHA) Classification <= 2 and baseline left ventricular ejection fraction (LVEF) >= 50% 13. Patients must be willing and able to sign a written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 144
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 24
排除标准
- •1. Previous or concomitant treatment with lapatinib and/or metformin 2. More than one line of prior hormone therapy for metastatic breast cancer 3. More than two lines of prior chemotherapy for metastatic breast cancer 4. Unique location of disease local-regionally treated (surgery, radiotherapy, other) 5. Disease progression not documented or less than 30% 6. Metastatic disease defined as aggressive at investigator’s judgement (e.g.. visceral disease more than >1/3 of involved parenchima, symptomatic disease requiring intensive supportive measures or therapies not allowed by protocol) 7. Patients with brain metastasis 8. Osteosclerotic bone metastasis as unique disease site 9. Pathological tumor markers as unique sign of progressive disease 10. Concomitant treatment with any other anticancer drugs (biphosphonates are permitted) 11. Serious, not solved or unstable toxicity from previous treatment 12. Diabetes mellitus Type I and Type II 13. Renal insufficiency (creatinine > 1.4 mg/ml) 14. Malabsorption syndrome or diseases that significantly may alter gastroenteric functions 15. Other serious illness or medical conditions judged by the investigator to be clinically significant that may adversely affect patient’s participation in the trial or interfere with safety profile 16. Active clinically significant or uncontrolled infections (bacterial or viral) 17. Known history of unstable angina (angina symptoms at rest), cardiac ventricular arrhythmias clinically significant, myocardial infarction, stroke or congestive heart failure within 12 months prior to randomization 18. History of lactic acidosis 19. Evidence or symptoms of hepatic insufficiency 20. Chronic alcoholism 21. Concomitant treatment with amiodarone or any other agent that could interfere with study drugs 22. Known or suspected hypersensitivity or allergy to lapatinib, metformin or used eccipients 23. Women who are pregnant or lactating 24. History of previous cancer, unless at low risk of relapse per investigator’s judgement
研究者
相似试验
已完成
2 期
Effect of hormonal therapy versus no treatment on testicular histopathology and fertility in patients with non-obstructive azoospermianon-obstructive azoospermia.Male infertilityIRCT201612069014N137Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences28
尚未招募
不适用
The effects of neoadjuvant hormonal therapy on the course of PSA and testosterone in patients with low and intermediate risk prostate carcinoma (NEO-ONE)prostate cancerprostate carcinoma10038588NL-OMON39212TweeSteden ziekenhuis400
进行中（未招募）
不适用
The effects of pretreatment with androgen blocking hormones before brachytherapy for prostate cancer on the course of PSA and testosterone after treatmentocalized prostate cancerMedDRA version: 14.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-004749-41-NLTweeSteden hospital
进行中（未招募）
1 期
Invloed van laag gedoseerde hormonale substitutie op insulinespiegels bij postmenopausale vrouweEUCTR2008-003661-19-BEniversity Hospital Ghent
进行中（未招募）
不适用
Effets du traitement hormonal substitutif et du raloxifène sur les cellules dendritiques plasmacytoïdes et les lymphocytes B chez les femmes ménopausées - EstrimmuneMenopauseEUCTR2009-017144-14-FRCentre Hospitalier de Toulouse